SARS-CoV-2 antibody vaccine response in Inflammatory Bowel Disease patients with positive anti-nucleocapsid serology or history of COVID-19 infection.
A HoyoisC GulkilikL MekkaouiH DahmaV WambacqC MinsartN RosewickC LiefferinckxL AmininejadA Van GossumA CremerO VandenbergD FranchimontPublished in: Acta gastro-enterologica Belgica (2024)
In Inflammatory Bowel Disease, prior COVID-19 infection or positive anti-nucleocapsid serology leads to increased anti-SARS-CoV-2 spike-specific IgG levels after vaccination, regardless of immunosuppressive treatments. This emphasizes the significance of accounting for previous infection in vaccination approaches.